S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Astria Therapeutics Stock Price, News & Analysis (NASDAQ:ATXS)

$4.75
+0.10 (+2.15%)
(As of 12/1/2023 ET)
Compare
Today's Range
$4.51
$4.80
50-Day Range
$4.42
$8.38
52-Week Range
$4.26
$16.28
Volume
310,194 shs
Average Volume
193,350 shs
Market Capitalization
$172.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.75

Astria Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
315.8% Upside
$19.75 Price Target
Short Interest
Healthy
1.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.35mentions of Astria Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$7 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.28) to ($2.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

143rd out of 951 stocks

Pharmaceutical Preparations Industry

51st out of 436 stocks


ATXS stock logo

About Astria Therapeutics Stock (NASDAQ:ATXS)

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

ATXS Stock Price History

ATXS Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Astria Therapeutics Presents Potential For STAR-0125 To Prevent HAE
Earnings Preview For Astria Therapeutics
Expert Ratings for Astria Therapeutics
See More Headlines
Receive ATXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATXS
Employees
45
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$19.75
High Stock Price Target
$25.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+315.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-51,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.46 per share

Miscellaneous

Free Float
35,062,000
Market Cap
$172.43 million
Optionable
Not Optionable
Beta
0.84

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Ms. Jill C. Milne Ph.D. (Age 55)
    Co-Founder, CEO, President & Director
    Comp: $928.52k
  • Mr. Benjamin S. Harshbarger J.D. (Age 54)
    Chief Legal Officer
    Comp: $621.91k
  • Mr. Noah Clauser CPA (Age 49)
    CFO & Treasurer
    Comp: $508.79k
  • Ms. Keri McGrail
    Senior Vice President of Human Resources
  • Ms. Andrea L. Matthews
    Chief Business Officer
  • Mr. Andrew A. KomjathyMr. Andrew A. Komjathy (Age 59)
    Chief Commercial Officer
  • Dr. Christopher J. Morabito M.D. (Age 53)
    Chief Medical Officer
  • Mr. John Ruesch
    Senior Vice President of Pharmaceutical Sciences & Technical Operations














ATXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Astria Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATXS shares.
View ATXS analyst ratings
or view top-rated stocks.

What is Astria Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 1 year target prices for Astria Therapeutics' shares. Their ATXS share price targets range from $18.00 to $25.00. On average, they predict the company's stock price to reach $19.75 in the next twelve months. This suggests a possible upside of 315.8% from the stock's current price.
View analysts price targets for ATXS
or view top-rated stocks among Wall Street analysts.

How have ATXS shares performed in 2023?

Astria Therapeutics' stock was trading at $14.89 at the start of the year. Since then, ATXS shares have decreased by 68.1% and is now trading at $4.75.
View the best growth stocks for 2023 here
.

When is Astria Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our ATXS earnings forecast
.

How were Astria Therapeutics' earnings last quarter?

Astria Therapeutics, Inc. (NASDAQ:ATXS) posted its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.31. During the same quarter in the prior year, the company posted ($3.36) earnings per share.

When did Astria Therapeutics' stock split?

Shares of Astria Therapeutics reverse split on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Who are Astria Therapeutics' major shareholders?

Astria Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (9.15%), Affinity Asset Advisors LLC (3.57%), Jacobs Levy Equity Management Inc. (0.58%), Stratos Wealth Partners LTD. (0.15%), Connor Clark & Lunn Investment Management Ltd. (0.15%) and Invesco Ltd. (0.09%). Insiders that own company stock include Andrew Komjathy and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Astria Therapeutics?

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ATXS) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -